BASF has entered an agreement with Sandoz GmbH, a subsidiary of Novartis, to invest at the Kundl/Schaftenau Campus in Austria. The agreement enables BASF to further develop its production footprint for enzymes and biotechnology products. Both parties agreed not to disclose financial details of the agreement.

“This investment is a clear sign of our commitment to the enzymes and biotechnology industry. BASF will strengthen its position in the market, as the Kundl/Schaftenau Campus has 75 years of biotechnology practice and corresponding infrastructure, including deep know-how,” said Dr. Michael De Marco, vice president global business management enzymes for BASF.

Senior Vice President Home Care, I&I and Industrial Formulators Europe Dr. Soeren Hildebrandt commented, “The agreement enables us to expand our production footprint for detergent enzymes and further enhance our product portfolio and leading market position in the Home Care and I&I industry. With this step we support our customers to address key market needs such as cleaning products with superior sustainability profiles and new product formats, based on innovative BASF enzyme technology.”

Steffen Lang, head of Novartis Technical Operations and member of the Novartis Executive Committee, said Tyrol is a key location for the company’s global production network. “Our investments in Kundl and Schaftenau reinforce our commitment to the region. With the further development into a Life Science Park and the settlement of BASF, an important player in the field of biotechnology, we are strengthening the competence and innovation capacity of the area.”

BASF said it is also seeking to explore the potential to grow further via deeper involvement in the Kundl/Schaftenau Campus. The start of production is planned for 2024.